Familial Risk Plays a Moderate Role in Substance-Induced Psychotic Disorder
Schizophrenia subsequent to substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome resulting from drug exposure.
Schizophrenia
Increased Protein Insolubility May Be Related to Subtype of Schizophrenia
Discovering the molecular mechanism of this subtype of schizophrenia could lead to the identification of novel therapeutic targets.
Leveraging Neuroimaging for the Diagnosis of Psychiatric and Neurodegenerative Diseases
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
Leveraging Pharmacogenetic Testing to Improve Treatment Adherence in Mental Illness
Leveraging pharmacogenetics for selecting treatments may benefit patients with treatment-resistant schizophrenia and other psychotic disorders.
Taking Into Account Drug-Drug Interactions When Prescribing Third-Generation Antipsychotics
Psychiatrists need to take into account possible drug-drug interactions when prescribing third generation antipsychotics to their patients with schizophrenia.
Valbenazine and Tetrabenazine Show Promise in Treating Tardive Dyskinesia
Valbenazine and tetrabenazine may represent promising options for the treatment of tardive dyskinesia in patients on long-term antipsychotic medications.
Novel Treatment for Schizophrenia Gets FDA’s Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…
Duration of Marriage at Conception May Increase Schizophrenia Risk in Offspring
Offspring born to couples married for less than 3 years have a small increased risk for schizophrenia.
Long-Acting Atypical Antipsychotics Compared in Patients Experiencing an Acute Exacerbation of Schizophrenia
Results from the phase 3b ALPINE study, which evaluated Aristada (aripiprazole lauroxil; Alkermes) and Invega Sustenna (paliperidone palmitate; Janssen) in patients experiencing an acute exacerbation of schizophrenia, showed that both of these long-acting injectable treatments effectively controlled schizophrenia symptoms
Cognitive Behavioral Therapy for Insomnia Effective for Patients With Schizophrenia
Cognitive behavioral therapy shows promise promoting sleep in patients with schizophrenia.
Next post in Schizophrenia and Psychoses
